PARP and PARG Inhibitors—New Therapeutic Targets in Cancer Treatment

• Published in: Pathology oncology research Vol. 16; no. 4; pp. 469 - 478
• Main Authors: Fauzee, Nilufer Jasmine Selimah, Pan, Juan, Wang, Ya-lan
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.12.2010; Springer Nature B.V
• Subjects: Animals; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Biomedical and Life Sciences; Biomedicine; Cancer; Cancer Research; Enzyme Inhibitors - pharmacology; Enzyme Inhibitors - therapeutic use; Glycoside Hydrolases - antagonists & inhibitors; Glycoside Hydrolases - metabolism; Humans; Immunology; Medical research; Molecular Targeted Therapy - methods; Neoplasms - drug therapy; Neoplasms - enzymology; Oncology; Pathology; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases - metabolism; Year 2000; PARP; PARG; PARP inhibitors; PARG inhibitors

Today, the number of cancer patients throughout the world is increasing alarmingly and as per the World Health Organisation (WHO) data and statistics the prediction for the year 2020 will be 15 million new cases as compared to only 10 million cases in year 2000 leaving us dumbfounded. A lot of effor...